10-Q · May 1, 2025
Glaukos reported Q1 2025 revenue of $106,664,000 (up from $85,622,000 in Q1 2024) and GAAP net loss per share narrowed to $(0.32) from $(0.82). Gross margin expanded to 77.2% and loss from operations improved to…
Earnings analysis · 10-Q
GKOS earnings analysis
Filed April 29, 2026 · Our reading of the company's report
The latest report
Glaukos Corporation (GKOS) reported a strong Q1 2026 performance with revenues of $150.6 million, surpassing expectations by 9.9%, and a narrower loss per share of -$0.18, better than the estimated -$0.28. Management…
Read full summary
Glaukos Corporation (GKOS) reported a strong Q1 2026 performance with revenues of $150.6 million, surpassing expectations by 9.9%, and a narrower loss per share of -$0.18, better than the estimated -$0.28. Management raised its revenue outlook for 2026 significantly to a range of $620 million to $635 million, implying robust growth momentum, chiefly from its glaucoma segment and new product launches.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.18
- Gross margin
- 78%
- Segment
- U.S. Glaucoma Products
- Segment
- Corneal Health Products
What stood out
-
Strong Revenue Growth
Revenue increased from $106.7 million in Q1 2025 to $150.6 million, a 41.1% jump year-over-year.
-
Improved Earnings Performance
EPS improved from -$0.34 in Q1 2025 to -$0.18 in Q1 2026, reflecting a better cost structure.
-
Increased Gross Margin
Gross margin rose to 78% in Q1 2026 from 77% a year earlier, driven by efficient production.
-
Raised Full-Year Revenue Guidance
Revised revenue guidance for 2026 to $620M-$635M, up from $600M-$620M.
-
Key Product Launch Contributions
International glaucoma product sales saw a growth of 23%, significantly impacting overall revenue.
-
Controlled Launch of Epioxa
Introduced Epioxa for keratoconus, anticipated to enhance future revenue streams.
What to watch
-
Uncertain Reimbursement Environment
Changes in reimbursement policies may disrupt adoption rates of new products like iDose TR and Epioxa.
-
Increasing Operating Expenses
Operating expenses rose to $137.1 million, up from $103 million year-over-year, impacting net losses.
-
Supply Chain Risks
Macroeconomic factors and geopolitical tensions could adversely affect logistics and raw material costs.
Management's outlook
Management anticipates strong sales growth driven by glaucoma product demand.
Earlier filings 4
10-Q · November 5, 2024
Q3 2024 results show solid top-line growth and margin stability but the company remains unprofitable and cash flow negative. Net sales rose to $96.67M while gross margin held at ~76.7%; diluted loss per share improved…
10-Q · August 2, 2023
Q2 2023 results showed top-line growth with improving operating performance but continued net losses and negative free cash flow. Net sales rose to $80,399 (Q2 2023) from $72,685 (Q2 2022) and operating loss narrowed to…
10-K · February 24, 2023
Glaukos positions itself as a diversified ophthalmic medical technology and pharmaceutical company with three principal end markets: glaucoma, corneal disorders and retinal diseases. The 2022 filing highlights strong…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.